Ascletis Pharma Advances in Obesity Treatment with ASC37 Development

Core Insights - Ascletis Pharma Inc. is focused on developing innovative treatments for metabolic diseases, with a significant breakthrough in selecting ASC37 for clinical development targeting obesity treatment [1][4] Development and Technology - ASC37 utilizes Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT), achieving an average absolute oral bioavailability of 4.2%, which is significantly higher than competitors like semaglutide, tirzepatide, and retatrutide by 9-, 30-, and 60-fold respectively [3][5] - The drug's exposure level is approximately 57 times that of retatrutide, with a half-life of about 56 hours, indicating potential for less frequent dosing, a feature preferred by patients [3][5] Regulatory and Strategic Plans - Ascletis plans to submit an Investigational New Drug Application (IND) to the U.S. FDA for ASC37 in the second quarter of 2026, demonstrating the company's commitment to addressing unmet needs in obesity treatment [4][5] - The company will host a conference call in Mandarin on December 1, 2025, to discuss ASC37's development and strategic direction in the obesity treatment landscape [4]